BridgeBio Pharma Inc
BBIO
Company Profile
Business description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Contact
3160 Porter Drive
Suite 250
Palo AltoCA94304
USAT: +1 650 391-9740
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
839
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
Funding the next wave of data center growth.
stocks
Chart of the Week: BHP’s growth story faces a reality check
China’s slowing economy could weigh on BHP’s future growth.
stocks
3 best ASX growth stocks to buy for the long term
Here’s three high-quality growth companies with wide moats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,978.80 | 34.20 | -0.38% |
| CAC 40 | 8,338.81 | 39.05 | -0.47% |
| DAX 40 | 24,830.98 | 84.51 | -0.34% |
| Dow JONES (US) | 52,146.42 | 406.55 | -0.77% |
| FTSE 100 | 10,600.37 | 28.13 | 0.27% |
| HKSE | 24,562.24 | 446.36 | -1.78% |
| NASDAQ | 25,520.24 | 361.70 | -1.40% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,694.68 | 79.90 | 0.59% |
| S&P 500 | 7,457.69 | 76.08 | -1.01% |
| S&P/ASX 200 | 8,796.70 | 20.10 | -0.23% |
| SSE Composite Index | 3,764.15 | 118.26 | -3.05% |